Table 3.
Course of pro-inflammatory mediators and drug doses in outcome groups
| Survivors | Non-survivors | P | |
|---|---|---|---|
| n = 11 | n = 9 | ||
| Inflammatory mediators | |||
| IL-6, pg/mL | |||
| I | 293 (17–60,152) | 475 (74–161,787) | 0.77 |
| H | 320 (31–60,152) | 761 (197–161,787) | 0.55 |
| F | 48 (4–426) | 133 (9–161,787) | 0.11 |
| IL-8, pg/mL | |||
| I | 573 (29–10,429) | 1,357 (98–12,741) | 0.26 |
| H | 843 (47–10,458) | 1,648 (225–12,741) | 0.41 |
| F | 85 (7–1,085) | 345 (52–12,741) | 0.04 |
| TNF-α, pg/mL | |||
| I | 49 (17–301) | 56 (9–79) | 0.46 |
| H | 66 (39–301) | 56 (19–90) | 0.30 |
| F | 30 (5–82) | 26 (5–90) | 0.94 |
| Elastase-α1-antitrypsin, ng/mL | |||
| I | 145 (10–716) | 131 (12–707) | 0.82 |
| H | 200 (18–721) | 168 (12–905) | 0.77 |
| F | 98 (18–570) | 160 (9–405) | 0.60 |
| Drug doses | |||
| Dopamine, μg/kg/min | |||
| I | 8 (0–19) | 17 (8–22) | 0.007 |
| H | 12 (0–19) | 19 (8–27) | 0.012 |
| F | 2 (0–16) | 19 (5–27) | <0.001 |
| Dobutamine, μg/kg/min | |||
| I | 0 (0–21) | 0 (0–22) | 0.23 |
| H | 0 (0–21) | 12 (0–30) | 0.11 |
| F | 0 (0–5) | 5 (0–30) | 0.07 |
| Norepinephrine, μg/kg/min | |||
| I | 0 (0–0.16) | 0 (0–0.13) | 0.15 |
| H | 0.05 (0–0.21) | 0.24 (0–0.34) | 0.004 |
| F | 0 (0–0.16) | 0.14 (0–0.34) | 0.002 |
Median (range) and Mann–Whitney U test
IL-6 (8) interleukin-6 (8), TNF-α tumor necrosis factor alpha, I initial, H highest, F final values in the course of time